Teleflex Incorporated · NYSE:TFX
Teleflex — J.P. Morgan Healthcare Conference 2017
13 slides from Teleflex's conference presentation, Jan 10, 2017
Slide 1: Teleflex Incorporated J.P. Morgan Healthcare Conference Investor Presentation
Teleflex Incorporated J.P. Morgan Healthcare Conference Investor Presentation
Slide 2: Important Information
Important Information 2 Forward Looking Statements This presentation and our discussion contain forward-looking information and statements, which inherently involve risks and uncertainties that could cause actual results to differ from those projected or implied in the forward–looking statements. Th
Slide 3: Our Company
Our Company 3 Business Overview Revenue by Market1 • NYSE listed – TFX 9% • Global provider of medical technology 6% products that enhance clinical benefits, improve patient and provider safety and reduce procedure costs 85% • Serving healthcare providers worldwide through a combination of our direc
Slide 4: Our Segments: Vascular North America
Our Segments 4 Vascular North America Revenue by Segment1 • Our vascular access products facilitate a variety of critical care therapies, including the administration of intravenous medications and other therapies and the measurement of blood 12% 19% pressure and taking of blood samples through a si
Slide 5: Our Segments: Anesthesia North America
Our Segments 5 Anesthesia North America Revenue by Segment1 Our anesthesia products include airway and pain management products • Our airway management products are designed to help 12% 19% eliminate airway related complications and improve 8% procedural efficiencies for patients in surgical, critic
Slide 6: Our Segments: Surgical North America
Our Segments 6 Surgical North America Revenue by Segment1 • Our surgical products include: • Ligation and closure products, including clips and sutures 12% 19% used in a variety of surgical procedures 8% 11% • Access ports used in minimally invasive surgical 13% procedures, including robotic surgery
Slide 7: Our Segments: EMEA and Asia
Our Segments 7 EMEA Revenue by Segment1 • Our EMEA segment designs, manufactures and distributes medical devices primarily used in critical care, surgical applications and 12% 19% cardiac care 8% 11% 13% • For the twelve months ended September 25, 2016, our EMEA 9% segment represented $510.4 million
Slide 8: Our Segments: OEM
Our Segments 8 OEM Revenue by Segment1 • Our OEM segment designs, manufactures and supplies devices and instruments for other medical device manufacturers 12% 19% 8% • Provides custom-engineered extrusions, diagnostic and 11% interventional catheters, sheath / dilator sets and kits, sutures, 13% per
Slide 9: Our Strategy
Our Strategy 9 Position Teleflex to succeed in the healthcare environment of the future Increased utilization Increased economic pressure Capitalize on Teleflex’s scope and size Take advantage of unique Teleflex opportunities Footprint consolidation Distributor to direct conversions
Slide 10: Key Investment Highlights
Key Investment Highlights 10 Diversified, global medical technology company Well-positioned to take advantage of favorable industry dynamics Leading market positions with established global brands Diversified customer and supplier base Strong cash flow generation and proven history of deleveraging a
Slide 11: Thank You
THANK YOU Veleflex:
Slide 12: Appendix
APPENDIX Veleflex:
Slide 13: September 25, 2016 LTM Revenue Data
September 25, 2016 LTM Revenue Data 13 Dollars in Thousands 2015 Revenue: $ 1,809,690 Less - Q1'15 Revenue: $ 429,430 Less - Q2'15 Revenue: $ 452,045 Less - Q3'15 Revenue: $ 443,714 Add - Q1'16 Revenue: $ 424,893 Add - Q2'16 Revenue: $ 473,553 Add - Q3'16 Revenue: $ 455,648 September 25, 2016 LTM Re